Metsera [MTSR] vs Corcept Therapeutics [CORT] Detailed Stock Comparison
Metsera
NASDAQ
Loading...
Corcept Therapeutics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Metsera wins in 5 metrics, Corcept Therapeutics wins in 9 metrics, with 0 ties. Corcept Therapeutics appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Metsera | Corcept Therapeutics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -25.57 | 78.71 | Metsera |
| Price-to-Book Ratio | 12.12 | 14.60 | Metsera |
| Debt-to-Equity Ratio | 0.24 | 1.04 | Metsera |
| PEG Ratio | -0.39 | -26.76 | Corcept Therapeutics |
| EV/EBITDA | -22.01 | 87.24 | Metsera |
| Profit Margin (TTM) | 0.00% | 18.67% | Corcept Therapeutics |
| Operating Margin (TTM) | 0.00% | 13.72% | Corcept Therapeutics |
| EBITDA Margin (TTM) | N/A | 13.72% | N/A |
| Return on Equity | -72.78% | 21.70% | Corcept Therapeutics |
| Return on Assets (TTM) | -46.37% | 8.36% | Corcept Therapeutics |
| Free Cash Flow (TTM) | $-100.08M | $195.90M | Corcept Therapeutics |
| 1-Year Return | 98.11% | 97.78% | Metsera |
| Price-to-Sales Ratio (TTM) | N/A | 12.97 | N/A |
| Enterprise Value | $4.92B | $8.95B | Corcept Therapeutics |
| EV/Revenue Ratio | N/A | 12.50 | N/A |
| Gross Profit Margin (TTM) | N/A | 98.23% | N/A |
| Revenue per Share (TTM) | $0 | $7 | Corcept Therapeutics |
| Earnings per Share (Diluted) | $-2.94 | $1.12 | Corcept Therapeutics |
| Beta (Stock Volatility) | N/A | 0.46 | N/A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Metsera vs Corcept Therapeutics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Metsera | 1.16% | 0.77% | 49.57% | 84.92% | 219.15% | 98.11% |
| Corcept Therapeutics | 1.93% | 7.09% | 26.14% | 33.01% | 20.36% | 79.81% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Metsera | 98.11% | 98.11% | 98.11% | 98.11% | 98.11% | 98.11% |
| Corcept Therapeutics | 97.78% | 230.09% | 399.17% | 2,197.95% | 2,308.85% | 1,704.22% |
News Based Sentiment: Metsera vs Corcept Therapeutics
Metsera
News based Sentiment: POSITIVE
October 2025 was a game-changing month for Metsera, dominated by Pfizer's acquisition offer and positive Phase 2b trial results for their obesity drug. These events dramatically alter the company's future and offer substantial value to investors, making it a highly significant development.
Corcept Therapeutics
News based Sentiment: MIXED
Corcept experienced a month of conflicting signals, with strong sales of Korlym countered by lowered revenue guidance and a projected earnings decline. The upcoming FDA decisions on relacorilant are critical catalysts, but the recent insider selling and mixed analyst ratings add complexity to the investment picture.
Performance & Financial Health Analysis: Metsera vs Corcept Therapeutics
| Metric | MTSR | CORT |
|---|---|---|
| Market Information | ||
| Market Cap | $5.48B | $9.29B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 4,450,330 | 733,300 |
| 90 Day Avg. Volume | 2,876,433 | 831,183 |
| Last Close | $52.50 | $89.85 |
| 52 Week Range | $12.30 - $54.47 | $42.01 - $117.33 |
| % from 52W High | -3.62% | -23.42% |
| All-Time High | $54.46 (Sep 22, 2025) | $117.33 (Mar 31, 2025) |
| % from All-Time High | -3.60% | -23.42% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.19% |
| Quarterly Earnings Growth | N/A | -0.01% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.19% |
| Operating Margin (TTM) | 0.00% | 0.14% |
| Return on Equity (TTM) | -0.73% | 0.22% |
| Debt to Equity (MRQ) | 0.24 | 1.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $4.28 | $6.04 |
| Cash per Share (MRQ) | $5.05 | $3.25 |
| Operating Cash Flow (TTM) | $-177,979,008 | $182.19M |
| Levered Free Cash Flow (TTM) | $-209,127,000 | $166.88M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Metsera vs Corcept Therapeutics
| Metric | MTSR | CORT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -25.57 | 78.71 |
| Forward P/E | -15.15 | 50.37 |
| PEG Ratio | -0.39 | -26.76 |
| Price to Sales (TTM) | N/A | 12.97 |
| Price to Book (MRQ) | 12.12 | 14.60 |
| Market Capitalization | ||
| Market Capitalization | $5.48B | $9.29B |
| Enterprise Value | $4.92B | $8.95B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 12.50 |
| Enterprise to EBITDA | -22.01 | 87.24 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.46 |
| Book Value per Share (MRQ) | $4.28 | $6.04 |
Financial Statements Comparison: Metsera vs Corcept Therapeutics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MTSR | CORT |
|---|---|---|
| Revenue/Sales | $0 | $157.21M |
| Cost of Goods Sold | N/A | $2.40M |
| Gross Profit | N/A | $154.81M |
| Research & Development | $57.19M | $60.74M |
| Operating Income (EBIT) | $-65.79M | $3.42M |
| EBITDA | $-60.87M | $3.88M |
| Pre-Tax Income | $-76.59M | $9.62M |
| Income Tax | $0 | $-10.93M |
| Net Income (Profit) | $-76.59M | $20.55M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MTSR | CORT |
|---|---|---|
| Cash & Equivalents | $588.34M | $89.82M |
| Total Current Assets | $594.74M | $438.50M |
| Total Current Liabilities | $90.74M | $143.07M |
| Long-Term Debt | $514,000 | $5.85M |
| Total Shareholders Equity | $505.39M | $683.29M |
| Retained Earnings | $-333.73M | $564.28M |
| Property, Plant & Equipment | $1.27M | $7.69M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MTSR | CORT |
|---|---|---|
| Operating Cash Flow | $-67.66M | $34.72M |
| Capital Expenditures | $-7,000 | $-104,000 |
| Free Cash Flow | $-54.35M | $5.02M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | MTSR | CORT |
|---|---|---|
| Shares Short | 8.64M | 10.81M |
| Short Ratio | 6.13 | 16.33 |
| Short % of Float | 0.62% | 0.14% |
| Average Daily Volume (10 Day) | 4,450,330 | 733,300 |
| Average Daily Volume (90 Day) | 2,876,433 | 831,183 |
| Shares Outstanding | 103.04M | 105.11M |
| Float Shares | 64.60M | 86.95M |
| % Held by Insiders | 0.18% | 0.12% |
| % Held by Institutions | 0.84% | 0.76% |
Dividend Analysis & Yield Comparison: Metsera vs Corcept Therapeutics
| Metric | MTSR | CORT |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |